

BEST AVAILABLE COPY

Page 1 of 1

Form PTO 1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. LAY-006CIA		Serial No. 09/494,088		
Information Disclosure Statement by Applicant				Applicant: Allison E. Willing et al.				
(Use several sheets if necessary)				Filed: January 28, 2000 Group: 1632				
U.S. Patent Documents								
Init.		Document No.	Date	Name	Class	Subclass	Filing Date	
Foreign Documents								
Translation								
Init.		Document No.	Date	Country	Class	Subclass	Yes	No
	1	WO 90/06757	06/28/1990	PCT (US)	A61K	35		X
	2	WO 94/10292	05/11/1994	PCT (US)	C12N	5/06		X
	3	WO 96/15224	05/23/1996	PCT (US)	C12N	5/00		X
	4	WO 97/33470	09/18/1997	PCT (US)	A01N	1/00		X
Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)								
	5	S. J. Pleasure et al., "Pure, Postmitotic, Polarized Human Neurons Derived from Ntera 2 Cells Provide a System for Expressing Exogenous Proteins in Terminally Differentiated Neurons", <u>Jr. of Neuroscience</u> , Vol. 12, No. 5, pp. 1802-1815, May 1992						
	6	T. Terao et al., "Lithium Chloride Stimulates Catecholamine Synthesis and Secretion in Cultured Bovine Adrenal Medullary Cells", <u>Bio. Psychiatry</u> , Vol. 31, No. 10, pp. 1038-1049, 1992 (no month)						
	7	M. Mena et al., "Effects of Dibutylrlyl Cyclic AMP and Terinoic Acid on the Differentiationof dopamine Neurons: Prevention of Cell Death by Dibutylrlyl Cyclic AMP", <u>Journal of Neurochemistry</u> , Vol. 65, No. 6, 2612-2620, 1995 (no month).						
	8	Layton BioScience Press Releases, No. 24, March 9, 1999; No. 25, February 15, 1999; No. 26, February 5, 1999; No. 27, February 5, 1999; No. 28, February 4, 1999; No. 29, February 1, 1999; No. 30, December 1, 1998; No. 31, December 1, 1998; reprinted [Internet] http://www.laytonbio.com/whatsnew.htm .						
Examiner					Date Considered			
Examiner: Initial if citation considered, whether or not citation is in conference with MPEP 609; Draw line through citation if not conformance and not considered. Include a copy of this form with the next communication to applicant.								

RECEIVED

JUL 23 2003

TECH CENTER 1600/2900

BEST AVAILABLE COPY

(Use several sheets if necessary)

L01-06CIP

09/494.088

McGrogan & Snable

1/28/2000

1643

[illegible]

RECEIVED

JUL 23 2003

TECH CENTER 1600/2900

[illegible]

~~BEST AVAILABLE COPY~~

OTHER DOCUMENTS (including letters, faxes, e-mails, etc.)			
			Ling et al. Exp. Neurol. vol. 149:411-423, 1998. "Differentiation of Mesencephalic Progenitor Cells..."
			Zigova and Sanberg. Science & Medicine, September/October 1999, pp. 18-27. "Neural Stem Cells for Brain Repair."

Ling et al. Exp. Neurol. vol. 149:411-423, 1998. "Differentiation of Mesencephalic Progenitor Cells..."

Zigova and Sanberg. *Science & Medicine*, September/October 1999, pp. 18-27. "Neural Stem Cells for Brain Repair."

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

L01-06CIP

Application Number

09/494,088

Applicant(s)

McGrogan & Snable

Filing Date

January 28, 2000

Group Art Unit

1643

*EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Sentman et al., Cell vol. 67(5):879-88, Nov. 29, 1991. "bcl-2 Inhibits Multiple Forms of Apoptosis..." (Medline abstract)

Lindvall. Nature Biotechnology Vol. 17:635-636, July 1999. "Engineering Neurons for Parkinson's Disease."

Wagner et al. Nature Biotechnology Vol. 17:653-659, July 1999. "Induction of a Midbrain Dopaminergic Phenotype in Nurrl-overexpressing Neural Stem Cells by Type 1 Astrocytes."

Mendez et al. J. Neurosci. Vol. 16(22):7216-7227, November 15, 1996. "Reconstruction of the Nigrostriatal Pathway by Simultaneous intrastriatal and Intranigral dopaminergic Transplants."

Adams et al. Biochem. Res. Vol. 21 (5):619-627, 1996. "Characterization and Transplantation of Two Neuronal Cell Lines with Dopaminergic Properties."

Pekosz et al. J. Virology. Vol. 70(8):5329-5335, Aug. 1996. "Induction of Apoptosis by La Crosse Virus Infection and Role of Neuronal Differentiation and Human bcl-2 Expression in Its Prevention."

Langeveld et al. Neurosci. Lett. Vol. 192:13-16, 1995. "Cultured Rat Striatal and Cortical Astrocytes Protect Mesencephalic Dopaminergic Neurons Against Hydrogen Peroxide Toxicity Independent of Their Effect on Neuronal Development."

Sanberg et al. Nature Medicine Vol. 3(10):1129-32, Oct. 1997. "Testis-Derived Sertoli Cells have a Trophic Effect on Dopamine Neurons and Alleviate Hemiparkinsonism in Rats."

RECEIVED

JUL 23 2003

TECH CENTER 1600/2900

BEST AVAILABLE COPY

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

L01-06CIP

Application Number

09/494,088

Applicant(s)

McGrogan & Snable

Filing Date

Dopaminergic Cells


Group Art Unit

1634

*EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)



Rosenblad et al. Glial Cell Line-Derived Neurotrophic Factor Increases Survival, Growth and Function of Intrastriatal Fetal Nigral Dopaminergic Grafts. Neuroscience. 1996, Vol. 75, No. 4, pages 979-985.

Li et al. Selective Inhibition of the Expression of Signal Transduction Proteins by Lithium in Nerve Growth Factor-Differentiated PC12 Cells Journal of Neuroscience. 1995, Vol. 65, pages 2500-2508.

J. Lopez-Lozano et al. Long-Term Improvement in Patients with Severe Parkinson's Disease after Implantation of Fetal Ventral Mesencephalic Tissue in a Cavity of the Caudate Nucleus: 5-yr Follow Up in 10 Patients. Journal of Neurosurgery. 1997, Vol. 86, pages 931-942.

BEST AVAILABLE COPY

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.